In Vivo Testing Services

In Vivo Testing Services

ProQinase has established a large panel of Subcutaneous and Orthotopic Tumor Models (including bioluminescence read-out) for testing the efficacy of novel therapeutic agents on primary tumors in animals. Moreover, models are available which allow studying the immune-modulatory effect of test compounds on metastasis formation (in syngeneic tumor models in immune competent animals) and tumor angiogenesis.

The service portfolio is supplemented by other study types (tolerability, PK, PD, etc.) and Hollow Fiber Assay.

The in vivo hollow fiber model is a fast and economic approach to select a suitable cell line for an in vivo efficacy study. The method allows simultaneous evaluation of test items with three different tumor cell lines under two different conditions (s.c. & i.p. implantation) within the same mouse.

Read more

 
Xenograft models are the most frequently used test systems for the evaluation of in vivo efficacy of novel anticancer drug candidates. Tumor cells are subcutaneously implanted on the flank of animals, mostly mice or rats, where they proliferate and form measurable tumors. In addition xenograft models are cost-effective.

Read more

 
Orthotopic models are ideally suited to test the anticancer efficacy of new drug candidates. For this type of in vivo models, tumor cells are implanted into their organ of origin. The organ-specific microenvironment induces tumor growth similar to that of the original tumor. For these orthotopic models, luciferase-transduced cell lines are used to allow the assessment of tumor growth via bioluminescence imaging (BLI).

Read more

 
Metastasis tumor models are designed to analyze the anti-metastasic effect of novel anti-cancer drug candidates. For this purpose luciferase-transduced tumor cells with high metastatic potential are either implanted orthotopically into their organs of origin, intravenously or intracardially. Metastasis formation can also be analyzed with bone marrow engraftment models, where luciferasetransduced leukemia cell lines are implanted intravenously.

Read more

 
The spheroid-based in vivo angiogenesis model allows to study the effect of pro- and anti-angiogenic compounds in a living organism. For this model spheroids from human endothelial cells (HUVECs) are implanted subcutaneously in mice in an extracellular matrix containing angiogenic growth factors. Subsequently, the formation of a human vasculature and the effect of treatment can be monitored in vivo and ex vivo. The in vivo angiogenesis model is suitable for testing the pro- or anti-angiogenic in vivo efficacy of antibodies or other biologicals and compounds.

Read more

 
Our panel of syngeneic models can be used for analysis of immune modulatory drugs as well as for investigation of additional effects of conventional anti-cancer drugs on the immune system. The immuno-oncology platform comprises a panel of syngeneic models and established protocols for the analysis of various cell subtypes of the immune system by flow cytometry. In addition to its standard syngeneic models, ProQinase offers proprietary syngeneic test systems.

Read more

 
Today, cancer research tends to focus on development of novel cancer immunotherapies. Syngeneic tumor models are advantageous providing a functional immune system to assess novel immunotherapeutic approaches. While classical syngeneic mouse models are based on the implantation of cultured cell lines, ProQinases’ mouse-derived isograft (MDI) tumor models are propagated in mice only. Hence, the major advantage of these novel spontaneous-derived or carcinogen-induced MDI tumor models is the preservation of primary tumor phenotype and intratumoral immune cell populations.

Read more